Hospital Formularies and E-Prescription: Where Access Is Decided After Reimbursement

Reimbursement is necessary for access, but it is not sufficient. A medicine can be listed and priced and still reach few patients, because prescribing is shaped by hospital formularies, treatment protocols and the electronic systems clinicians use every day.

Hospital formularies

In many European systems hospitals manage their own lists of medicines, often through a drugs and therapeutics or formulary committee. Such committees typically weigh clinical value, safety, cost and fit with local protocols. Being nationally reimbursed does not guarantee a place on the list, and in some hospitals clinicians must request a non-formulary product case by case.

  • Identify who sits on the committee and what evidence they ask for.
  • Prepare a short, hospital-specific summary: place in therapy, patient numbers, budget impact and implementation needs.
  • Be ready to explain what the product replaces, not only what it adds.

Procurement shapes choice

In public hospitals, purchasing often runs through tenders and framework contracts, so access is closely linked to price competition and to how products are grouped for bidding. Understanding the procurement route in each market is as important as understanding the reimbursement route.

E-prescription as a steering tool

Greece has had a national e-prescription platform for well over a decade, established under Law 3892/2010 and operated through IDIKA. Because every prescription passes through the system, it is also a monitoring tool. Greek policy has used it to support therapeutic prescribing protocols, compliance with which has been made mandatory for physicians, and to track prescribing against targets, including generic prescribing thresholds. Independent analysis suggests the integration of protocols into the platform remains partial, so the practical constraints on prescribing can differ from the formal ones.

What this means for launch planning

  • Check whether the product, or its class, is covered by a prescribing protocol, and whether the protocol will need updating.
  • Understand how the product is entered in the e-prescription system, and any restrictions on who may prescribe it.
  • Plan hospital formulary submissions to follow reimbursement closely, rather than starting months afterwards.
  • Keep product information, packaging data and codes accurate, since errors in these can delay both dispensing and tendering.

A short checklist

  • Which hospitals and committees matter most for the product, and what do they require?
  • Is there an existing protocol covering the class, and does it need amending?
  • Are the e-prescription entries and product data accurate at launch?
  • Has the procurement route been mapped and priced into the launch plan?

Working through these points before the reimbursement decision can shorten the time from listing to the first patient treated.

How PQRA helps

PQRA helps companies understand the procedures and documents that sit between a reimbursement decision and real patient access in Greece, including the regulatory data that feeds prescribing and procurement systems, and aligns these steps with launch timelines. Hospital-level commercial engagement remains with your own teams.

Ready to discuss your market access plan? Contact PQRA to talk through your product and your target markets.

CATEGORIES:

Uncategorized

Tags:

No responses yet

Leave a Reply

Your email address will not be published. Required fields are marked *